Full-Time
Posted on 3/6/2025
Biotechnology company for cancer detection and prevention
$42k - $67kAnnually
Entry, Junior
No H1B Sponsorship
Madison, WI, USA
Exact Sciences focuses on the early detection and prevention of cancer through advanced diagnostic tests. Their products are designed to identify cancer at its earliest stages, which helps healthcare providers make informed treatment decisions. The company operates globally, serving healthcare providers, patients, and research institutions in the medical diagnostics market. Unlike many competitors, Exact Sciences emphasizes a comprehensive approach that includes not only the development and sale of cancer screening tests but also support for patients and healthcare professionals. The main goal of Exact Sciences is to reduce the burden of cancer by providing effective solutions for early detection and treatment guidance.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Madison, Wisconsin
Founded
1995
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Paid Vacation
Parental Leave
401(k) Retirement Plan
Wellness Program
Stock Options
MADISON, Wis.-(BUSINESS WIRE)-Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2025 Gallup Exceptional Workplace Award (GEWA), marking the second year in a row the company has received this prestigious recognition.
What You Should Know:– Flatiron Health, a leading technology company focused on improving cancer care announced a strategic partnership with Exact Sciences, a pioneer in cancer screening and diagnostics to accelerate clinical evidence generation for Exact Sciences’ molecular residual disease (MRD) test, Oncodetect™.– The collaboration will leverage Flatiron’s innovative clinical research platform and extensive network of community oncology practices to study the test’s performance in diverse patient populations and real-world settings.Leverage Real-World Data and Community Oncology Settings to Advance Cancer CareMRD testing is a rapidly evolving field in oncology, with the potential to transform cancer care by detecting residual disease after treatment and guiding personalized treatment decisions. However, generating robust clinical evidence for MRD tests can be challenging and time-consuming.This partnership aims to address this challenge by:Leveraging real-world data: Utilizing data from Flatiron’s network of community oncology practices to generate evidence in a real-world setting.Utilizing data from Flatiron’s network of community oncology practices to generate evidence in a real-world setting. Focusing on diverse patient populations: Ensuring that the study includes a broad range of patients, including those typically underrepresented in clinical trials.Ensuring that the study includes a broad range of patients, including those typically underrepresented in clinical trials. Accelerating evidence generation: Employing a novel prospective clinical evidence generation platform and pragmatic study design to expedite the research process.First Patient EnrolledThe partnership has already achieved a significant milestone with the enrollment of the first patient in the study in under six months from conception. This rapid progress highlights the strong collaboration and commitment to execution between Flatiron Health and Exact Sciences.“Our partnership with Exact Sciences leverages Flatiron’s next-generation prospective evidence platform, which we designed to address critical evidence gaps via studies embedded into routine care, with unprecedented speed,” said Alex Deyle, general manager, Clinical Research, Flatiron Health. “Our in-house team of experts, experienced site network, fit-for-purpose research operations, and cutting-edge technology that focuses on reducing site burden, has enabled us to run more efficient and representative prospective studies.”
Retirement Wealth Solutions LLC invests $327,000 in Exact Sciences Co. (NASDAQ:EXAS).
Notably, Exact Sciences is also working on its own blood-based test for colorectal cancer screening.
Exact Sciences Corporation announces appointment of Kim Popovits as A Class I member of the Board.